National Comprehensive Cancer Network



NCCN Oncology Research Program (ORP)
NCCN Volasertib Research Grant Opportunity – Submit by October 30, 2014
NCCN ORP Recent News
NCCN ORP Affiliate Research Consortium
NCCN ORP Scientific Publications
NCCN ORP for Industry
NCCN ORP Investigator Steering Committee
NCCN ORP Testimonials
NCCN Clinical Trials at NCCN Member Institutions
Find NCCN ORP Funded Clinical Trials at NCCN Member Institutions
NCCN Informed Consent Language Database
NCCN Specialized Imaging Research Consortium™ (SIRC)
NCCN ORP Disclosure Policy
NCCN Collaboration with the National Business Group on Health
NCCN Health Information Technology Licensees

NCCN Research & Business Resources

Trastuzumab Added to Esophageal and Gastric Cancer Guidelines

The NCCN Clinical Practice Guidelines in Oncology™ for Esophageal Cancer and the NCCN Clinical Practice Guidelines in Oncology™ for Gastric Cancer have been updated and published. Both Guidelines are now available in v.1.2010.

Trastuzumab in combination with systemic chemotherapy was added to the Esophageal and Gastric Cancer Guidelines as an option for the treatment of patients with advanced esophageal cancer, gastric cancer, or GE junction adenocarcinoma that is HER-2-positive as determined by a standardized method.